Tyrosine kinase inhibitor neratinib attenuates liver fibrosis by targeting activated hepatic stellate cells

Liver fibrosis, a common outcome of chronic liver disease characterized by excessive accumulation of extracellular matrix (ECM), is a leading cause of mortality worldwide. The tyrosine kinase inhibitor neratinib is a human epidermal growth factor receptor 2 (HER2) inhibitor approved by the FDA for H...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Sci Rep
Prif Awduron: Park, Yong Joo, An, Hyoung-Tae, Park, Jong-Sung, Park, Ogyi, Duh, Alexander J., Kim, Kwangmeyung, Chung, Kyu Hyuck, Lee, Kang Choon, Oh, Yumin, Lee, Seulki
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7479613/
https://ncbi.nlm.nih.gov/pubmed/32901093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-71688-2
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg